MedPath

TBTC Study 25PK: Intensive Pharmacokinetic Study of Three Doses of Rifapentine and 25-Desacetyl Rifapentine

Not Applicable
Completed
Conditions
Tuberculosis
Registration Number
NCT00023387
Lead Sponsor
Centers for Disease Control and Prevention
Brief Summary

Primary objective: To compare the pharmacokinetics of rifapentine and 25-desacetyl rifapentine at three different doses: 600 mg, 900 mg, and 1200 mg.

Secondary objective: To describe any correlation between pharmacokinetic parameters of three different doses of rifapentine plus a standard dose of isoniazid and the occurrence of toxicity attributed to anti-tuberculosis treatment.

Detailed Description

We will enroll 24-36 patients, 8-12 at each dose of 600, 900 and 1200 mg rifapentine Admissions for pharmacokinetic studies will take place during the continuation phase of tuberculosis therapy. Patients participating in a double-blinded trial of the tolerability and safety of higher doses of rifapentine during continuation phase therapy and consenting to participate in the pharmacokinetic study may be admitted to a Clinical Research Center (CRC) to allow for frequent blood sampling over a 24-hour period. Otherwise, patients will be evaluated in the clinic.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
36
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Compare the pharmacokinetics of rifapentine and 25-desacetyl rifapentine at three difference doses: 600 mg, 900 mg, and 1200 mg
Secondary Outcome Measures
NameTimeMethod
Describe any correlation between pharmacokinetic parameters of three different doses of rifapentine plus a standard dose of isoniazid and the occurrence of toxicity attributed to anti-tuberculosis treatment.

Trial Locations

Locations (23)

Central Arkansas Veterans Health System

🇺🇸

Little Rock, Arkansas, United States

LA County/USC Medical Center

🇺🇸

Los Angeles, California, United States

University of California, San Francisco

🇺🇸

San Francisco, California, United States

Denver Department of Public Health and Hospitals

🇺🇸

Denver, Colorado, United States

Washington, D.C. VAMC

🇺🇸

Washington, District of Columbia, United States

Chicago VA Medical Center (Lakeside)

🇺🇸

Chicago, Illinois, United States

Hines VA Medical Center

🇺🇸

Hines, Illinois, United States

Johns Hopkins University School of Medicine

🇺🇸

Baltimore, Maryland, United States

Boston Medical Center

🇺🇸

Boston, Massachusetts, United States

New Jersey Medical School

🇺🇸

Newark, New Jersey, United States

Scroll for more (13 remaining)
Central Arkansas Veterans Health System
🇺🇸Little Rock, Arkansas, United States

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.